Silicone breast implant policy: FDA designee is needed to find "solution" -- Rep. Shays.
This article was originally published in The Gray Sheet
Executive SummarySILICONE BREAST IMPLANTS: FDA DESIGNEE NEEDED TO FIND "SOLUTION" to the current regulatory status of the devices, Rep. Christopher Shays (R-Conn.) told FDA Commissioner David Kessler at an Aug. 1 hearing on silicone breast implants. The joint hearing was held by the House Government Reform/Human Resources Subcommittee, chaired by Shays, and the National Economic Growth Subcommittee.
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.